Safrazine is an irreversible, non-specific and orally active monoamine oxidase (MAO) inhibitor. Safrazine can be used in depression research[1].

Safrazine (0.1-0.5 μM; 0-80 min) enhances the inhibitory potency by preincubation in a time-dependent manner [1].

Safrazine (oral; 3, 10, 30 mg/kg) results in the increases contents of monoamine lasted for at least 24 h [1]. Safrazine strongly inhibits both 5-HT and PEA deaminations, but shows no selectivity toward the substrate used [1]. Animal Model: Male ddY mice [1] Dosage: 3, 10, 30 mg/kg Administration: Oral Result: Inhibited significantly both 5-HT and PEA deaminations at only 3 mg/kg by 77% and 71%, respectively. Completely reduced both deaminations at 10 and 30 mg/kg and not observed specificity toward substrates.